It is possible that GLP-1 signalling in AIS patients could be impaired given the occurrence of G inhibitory proteins malfunction in AIS68 and the role of cyclic adenosine monophosphatase (cAMP) as a key mediator of the GLP-1 pathway71. The gene discussed is GCG; the disease is androgen insensitivity syndrome.